Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,541 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M. The company achieved key milestones including generic Ventolin approval and crossing 12,500 Cr in India revenue. Management guided for FY27 EBITDA margins of 18.5-20% with sequential improvement, driven by US respiratory launches and India chronic portfolio expansion. The US business targets a $1B run-rate by FY27-end, supported by 4 respiratory approvals and a peptide launch. Key risk: geopolitical disruptions and war-related cost inflation could pressure near-term margins.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects EBITDA margins in the range of 18.5-20% for FY27, with sequential improvement and stronger H2.
- Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.
- Management expects strong double-digit and market-beating growth in India for FY27 and FY28.
- R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.
Risks flagged
- Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
- Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
- Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.
- Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance.
Key quotes
- We are expecting to launch this product within the coming months. Our Goa facility together with two US facilities is well equipped to support the launch of all four respiratory assets planned for FI27.
- We expect the EBITDA margins to be in the range of 18.5% to 20%... this guidance does not include any contribution from lanreotide in FY27.
- We are confident that we'll be able to deliver a strong double-digit growth as well as a market beating growth in FI27-28.
Research modules